INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

NCT03837509 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped This decision follows recruitment difficulties. No safety-related concerns impacted this decision.

Conditions

Interventions

Sponsor

Incyte Corporation